anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses traditional Chinese medicine and a machining technology thereof, which belongs to the technical field of the traditional Chinese medicine, and the traditional Chinese medicine is used for treating coronary heart disease angina pectoris and is also used for preventing and treating cerebrovascular disorder diseases. The traditional Chinese medicine is composed of the raw materials of the following ratios by weight: 150 to 450 parts of american ginseng, 400 to 800 parts of sanchi, 0.3 to 3 parts of dryobalanops aromatica and 10 to 50 parts of rosewood. The present invention uses the sanchi capable of activating blood circulation and dissipating blood stasis as a monarch, the american ginseng capable of supplying vacuity, strengthening body resistance and improving effect as a minister, the rosewood capable of regulating qi, dissipating blood stasis and strengthening the effects of activating blood circulation and dissipating blood stasis of the sanchi as an assist and the dryobalanops aromatica capable of leading all the medicine to penetrate into the whole body as a messenger. The medicine of the present invention is simple and is not complicated, the medicine has the monarch, the minister, the assist and the messenger, and the medicine can treat the diseases and can also supply a body. The traditional Chinese medicine can be suitable for the treatment of the diseases and health-care maintenance, the taste of the medicine is soft, and the traditional Chinese medicine can be taken by heat and cold patients. The traditional Chinese medicine has the characteristics of high treating effect, low medicine expense, convenient taking, no toxic side effect, no contraindication, safety, reliability, convenient grasp, convenient use, high effect taking speed and short treating course, and the effective rate of the traditional Chinese medicine can reach 98%.
All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \<10 lx. In the second experimental session, they receive an intensity of \~100 lx, and in the third experimental session, they receive an intensity of \>1000 lx.
The present invention provides a method of sustaining direct delivery of cells into a target area. The method generally includes delivering cells to a target area. Specifically, the cells are introduced through an introduction site of a target area and delivered to the target area. The method further includes depositing at the introduction site, a plug member that contains a therapeutic agent that is released from the plug member to the target site. at the introduction site. The therapeutic agent generally acts to increase intracellular coupling between the grafted cells and the target area. The plug member also acts to seal the introduction site to inhibit cells from leaking from the introduction site into surrounding areas of the body.
This study will be a double-blind randomized controlled trial, parallel in two groups (intervention group and sham). Participants will initially be evaluated by a trained investigator who will be blinded and assigned randomly (random numbers generated on the computer) block for the intervention and sham groups by an opaque envelope draw. Participants will be randomized into two groups: intervention and sham. Both groups will undergo a kinesiotherapy program once a week for 6 consecutive weeks.

Also, participants in the intervention group will receive, once a week, a manual therapy protocol, while participants in the Sham group will receive traditional massage. When making the invitation to participate in the survey, individuals will not be required to participate if they do not agree, and therefore will not be penalized. Participants who agree to participate in the survey will sign a Free and Informed Consent Form and will be informed of the possibility of withdrawing from the survey at any stage, without penalty. The collection of the evaluation and intervention will be carried out in a salon Clinic School of Physiotherapy in the Center of Health and Sports Sciences (CEFID) of the State University of Santa Catarina (UDESC) in the city of Florianópolis- SC. All personal identification data of the participants will be preserved according to resolution of the national health council, taking into account the possibility of scientific dissemination of the results obtained. The risks of these procedures will be medium, since the participant may present muscle pain after the intervention protocol. To minimize these risks will be available, if necessary, attendance at the Clinic School of Physiotherapy. The sample will be selected in a non-probabilistic way for convenience. This study will include women diagnosed with breast cancer who have undergone breast surgery with curative intent and who have completed chemotherapy and / or radiotherapy treatments.
Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
The prevalence of obesity continues to rise, and public health dietary recommendations are not being adhered to. The transition to higher education is a period of risk for weight gain in young adults and has been demonstrated as a good time to initiate behaviour change. A genotype-based personalised approach to dietary recommendations may motivate young adults to maintain or adopt positive dietary behaviours. The aim of the present study was to determine the efficacy of genotype-based personalised dietary and physical activity advice on healthy eating motivation in young adults. Participants were young adults (n = 153), aged 18-25 years. Baseline measures (participant characteristics, height, weight, body mass index [BMI], body fat percentage [BF%], healthy eating motivation and physical activity) were collected. Participants were genotyped for a SNP in the FTO gene (rs99396090) and randomly allocated (stratified for genotype) to three different groups (1. Genotype-based personalised advice: dietary and physical activity advice based on genotype, BMI and reported physical activity; 2. Non-genotype-based personalised advice: dietary and physical activity advice based on BMI and reported physical activity; 3. Control: no advice). A week after receipt of advice delivered via email, participants completed the healthy eating motivation questionnaire for a second time. Genotype-based personalised dietary advice did not affect healthy eating motivation: when participants were analysed across the whole group (p = 0.417), when analysed according to those informed of a risk or non-risk-associated genotype (p = 0.287), or when analysed according to those with a BMI (>25 kg/m2; p = 0.336) or BF% (male >18%, female >31%; p = 0.387) outside the healthy range. There was also no significant difference in healthy eating motivation at 1-week in the control or non-genotype-based advice groups. Genotype-based personalised advice for the prevention of obesity did not affect healthy eating motivation in this group of healthy, young adults.
Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
The purpose of the clinical study is to evaluate the safety and microbiology of C16G2 administered in multiple oral gel doses to adolescent and adult dental subjects. Subjects will be assigned to three study cohorts and receive 2 different volumes of C16G2 Gel or Placebo. Prior to commencing enrollment of subjects 12-17 years of age, a safety only cohort of 4-8 adolescent subjects will receive 4 study drug administrations on Day 0. A safety data review will be performed by the Medical Monitor on Days 1 and 5. If no safety concerns are identified, enrollment of adolescent subjects receiving 7 days of study drug administration will be initiated in Study Arms 1 \& 2. Enrollment of adult subjects in Study Arms 1 \& 2 may start before the Adolescent Safety Only Cohort is initiated. Before dosing of study drug, eligible subjects will undergo professional dental prophylaxis on Day 0. Microbiology will be assessed by measuring S. mutans and total bacteria counts.
The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome. This invention addresses the need mentioned above by providing agents and methods for treating or ameliorating symptoms of neurologic diseases, such as autism spectrum disorders and Rett Syndrome. In one aspect, the invention provides a method for treating a neurologic disease associated with one or more mutations in the MECP2 gene. In another aspect the invention provides a method for treating Rett Syndrome, comprising administering to a human subject in need thereof an effective amount of a therapeutic agent that is {[2-bromo-4-(2 carbamoyl-2methanesulfonylaminoethyl)phenyl]difluoromethyl}-phosphonic acid (CPT157633). In a further aspect, the invention provides a system comprising a first pharmaceutical composition comprising an effective amount of a first therapeutic agent that is a small molecule inhibitor of PTP1B, and a kit for diagnosing Rett Syndrome, as well as a composition comprising a small molecule inhibitor of PTP1B for use in treatment of a neurologic disorder characterized by mutations in the MECP2 gene. WO 2016/049110 PCTIUS2015/051594 All
Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
1,132,021. Purified gonadotropins. ORGANON LABORATORIES Ltd. 3 Jan., 1966 [13 Jan., 1965], No. 81/66. Heading ASB. A crude gonadotropin preparation is purified by precipitation with an alcohol, e.g. MeOH, EtOH or PrOH, in an acid medium, there being first obtained a clear solution of the preparation containing a mole fraction of an alcohol of at least 0.33 having a pH value higher than 6 up to and including 9 and containing at least one salt which is soluble in water-alcohol mixtures with a mole fraction of at most 0.016 and a mole fraction of water from 0.50 to 0.65, and at least one acid being added thereto until the measured pH has reached a value in the range 3 to 6 inclusive while simultaneously raising the alcohol concentration for a selective precipitation of the gonadotropin, which may then be isolated and recovered. The salt may be the ammonium salt of the organic aoids which may be used in the precipitation, or salts of these acids with an amine, e.g. aniline, pyridine, pyridazine, pyrazine, pyrrol, imidazol, methylamine, ethylamine, dimethyl or diethylamine or derivatives of these amines, or salts of quaternary ammonium bases, such as trihydroxymethlaminomethane and ethylene diamine tetraacetic acid. The acid used in the precipitation may be HCl and/or a water-soluble organic acid, e.g. formic, acetic, propionic, butyric, malonic, succinic, mono- or tri-chloro acetic, citric, lactic, tartaric, glutamic, aspartic or unsaturated carboxylic acids. In the purification of a crude human menopausal gonadotropin preparation, the alcohol concentration may be raised until a mole fraction of about 0.40 has been reached to precipitate any follicle-stimulating hormone-containing substance which is present.
For some communicable endemic diseases (e.g., influenza, COVID-19), vaccination is an effective means of preventing the spread of infection and reducing mortality, but must be augmented over time with vaccine booster doses. We consider the problem of optimally allocating a limited supply of vaccines over time between different subgroups of a population and between initial versus booster vaccine doses, allowing for multiple booster doses. We first consider an SIS model with interacting population groups and four different objectives: those of minimizing cumulative infections, deaths, life years lost, or quality-adjusted life years lost due to death. We solve the problem sequentially: for each time period, we approximate the system dynamics using Taylor series expansions, and reduce the problem to a piecewise linear convex optimization problem for which we derive intuitive closed-form solutions. We then extend the analysis to the case of an SEIS model. In both cases vaccines are allocated to groups based on their priority order until the vaccine supply is exhausted. Numerical simulations show that our analytical solutions achieve results that are close to optimal with objective function values significantly better than would be obtained using simple allocation rules such as allocation proportional to population group size. In addition to being accurate and interpretable, the solutions are easy to implement in practice. Interpretable models are particularly important in public health decision making.
Gut microbial homeostasis is crucial for the health of cognition in elderly. Previous study revealed that polysorbate 80 (P80) as a widely used emulsifier in food industries and pharmaceutical formulations could directly alter the human gut microbiota compositions. However, whether long-term exposure to P80 could accelerate age-related cognitive decline via gut-brain axis is still unknown. Accordingly, in this study, we used the senescence accelerated mouse prone 8 (SAMP8) mouse model to investigate the effects of the emulsifier P80 intake (1 % P80 in drinking water for 12 weeks) on gut microbiota and cognitive function. Our results indicated that P80 intake significantly exacerbated cognitive decline in SAMP8 mice, along with increased brain pathological proteins deposition, disruption of the blood-brain barrier and activation of microglia and neurotoxic astrocytes. Besides, P80 intake could also induce gut microbiota dysbiosis, especially the increased abundance of secondary bile acids producing bacteria, such as Ruminococcaceae, Lachnospiraceae, and Clostridium scindens. Moreover, fecal microbiota transplantation from P80 mice into 16-week-old SAMP8 mice could also exacerbated cognitive decline, microglia activation and intestinal barrier impairment. Intriguingly, the alterations of gut microbial composition significantly affected bile acid metabolism profiles after P80 exposure, with markedly elevated levels of deoxycholic acid (DCA) in serum and brain tissue. Mechanically, DCA could activate microglial and promote senescence-associated secretory phenotype production through adenosine triphosphate-binding cassette transporter A1 (ABCA1) importing lysosomal cholesterol. Altogether, the emulsifier P80 accelerated cognitive decline of aging mice by inducing gut dysbiosis, bile acid metabolism alteration, intestinal barrier and blood brain barrier disruption as well as neuroinflammation. This study provides strong evidence that dietary-induced gut microbiota dysbiosis may be a risk factor for age-related cognitive decline.
BACKGROUND: Alzheimer's Disease (AD) is the most common form of dementia. Its early stage, amnestic Mild Cognitive Impairment (aMCI), is characterized by disrupted information flow in the brain. Previous studies have yielded inconsistent results when using electrophysiological techniques to investigate functional connectivity changes in AD, and a contributing factor may be the study of brain activity divided into frequencies.
METHODS: Our study aimed to address this issue by employing a cross-frequency approach to compare the functional networks of 172 healthy subjects and 105 aMCI patients. Using magnetoencephalography, we constructed source-based multilayer graphs considering both intra- and inter-frequency functional connectivity. We then assessed changes in network organization through three centrality measures, and combined them into a unified centrality score to provide a comprehensive assessment of centrality disruption in aMCI.
RESULTS: The results revealed a noteworthy shift in centrality distribution in aMCI patients, both in terms of spatial distribution and frequency. Posterior brain regions decrease synchrony between their high-frequency oscillations and other regions' activity across all frequencies, while anterior regions increase synchrony between their low-frequency oscillations and other regions' activity across all frequencies. Thus, posterior regions reduce their relative importance in favor of anterior regions.
CONCLUSIONS: Our findings provide valuable insights into the intricate changes that occur in functional brain networks during the early stages of AD, demonstrating that considering the interplays between different frequency bands enhances our understanding of AD network dynamics and setting a precedent for the study of functional networks using a multilayer approach.
ADALAT® CC is an extended release tablet dosage form of the calcium channel blocker nifedipine. Nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dimethyl ester, C17H18N2O6, and has the structural formula:

Nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 346.3. ADALAT CC tablets consist of an external coat and an internal core. Both contain nifedipine, the coat as a slow release formulation and the core as a fast release formulation. ADALAT CC tablets contain either 30, 60, or 90 mg of nifedipine for once-a-day oral administration.

Inert ingredients in the formulation are: hydroxypropylcellulose, lactose, corn starch, crospovidone, microcrystalline cellulose, silicon dioxide, and magnesium stearate. The inert ingredients in the film coating are: hypromellose, polyethylene glycol, ferric oxide, and titanium dioxide.
Allow 7 to 14 days to elapse after bladder biopsy before TICE BCG is administered. Patients should not drink fluids for 4 hours before treatment and should empty their bladder prior to TICE BCG administration. The reconstituted TICE BCG is instilled into the bladder by gravity flow via the catheter. After instillation of the TICE BCG suspension is complete, remove the catheter. The TICE BCG is retained in the bladder for 2 hours and then voided. Patients unable to retain the suspension for 2 hours should be allowed to void sooner, if necessary.

While the BCG is retained in the bladder, the patient ideally should be repositioned from left side to right side and also should lie upon the back and the abdomen, changing these positions every 15 minutes to maximize bladder surface exposure to the agent.

A standard treatment schedule consists of 1 intravesical instillation per week for 6 weeks. This schedule may be repeated once if tumor remission has not been achieved and if the clinical circumstances warrant. Thereafter, intravesical TICE BCG administration should continue at approximately monthly intervals for at least 6 to 12 months. There are no data to support the interchangeability of BCG LIVE products.
BACKGROUND: The cardiovascular system is among the least systems affected by immune-related adverse events. We report a rare life-threatening case of pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient.
CASE PRESENTATION: An 82-year-old Caucasian female with invasive urothelial carcinoma, started on first-line pembrolizumab, was admitted four days after receiving her second dose for severe asthenia, diffuse muscle aches, neck pain, and lethargy. In the emergency department, she had several episodes of bradycardia reaching 40 beats per minute associated with general discomfort and fatigue. Electrocardiography showed a third-degree atrioventricular heart block, while the patient remained normotensive. Cardiac damage parameters were altered with elevated levels of creatine phosphokinase of 8930 U/L, suggestive of immune checkpoint inhibitor-induced myositis, and troponin T of 1.060 ng/mL. Transthoracic echocardiography showed a preserved ejection fraction. Pembrolizumab-induced myocarditis was suspected. Therefore, treatment was initiated with high-dose glucocorticoids for 5 days, followed by a long oral steroid taper. A pacemaker was also implanted. Treatment resulted in the resolution of heart block and a decrease in creatine phosphokinase to the normal range.
CONCLUSION: Life-threatening cardiac adverse events in the form of myocarditis may occur with pembrolizumab use, warranting vigilant cardiac monitoring. Troponin monitoring in high-risk patients, along with baseline echocardiography may help identify this complication promptly to prevent life-threatening consequences.
FIELD: medicine. SUBSTANCE: method involves dissecting in wide cut gastrocolic ligament, evacuating pyonecrotic mass from the pancreas region and parapancreatic fat, bringing drainage tubes to the head, body and tail of the pancreas and forming additional drainage canal isolated from the abdominal cavity made from the greater omentum between the retroperitoneal space and the inferior angle of the laparotomic wound. To do it, a 6x4 cm wide window is made in the central part of the greater omentum corresponding to the projection of the inferior boundary of the retroperitoneal fat lesion. The boundary of this window is sutured to the posterior parietal peritoneum in the region of the lower pole of the retroperitoneal fat lesion. The free edges of the greater omentum are sutured to the parietal peritoneum of the inferior corner of the laparotomic cut, a portion of the posterior parietal peritoneum restricted by the window is dissected and additional drainage tubes and rubber-gauze tampons are introduced into the retroperitoneal space through the formed drainage canal. Pancreas and retroperitoneal fat region are washed twice a day during the first two days in the postoperative period. Permanent infusion with 0.02% chlorohexidine aqueous solution is carried out at the third day in the amount of 2.0-2.5 l per day through tubes located near the head, body and tail of the pancreas until pus and sequesters stop discharging. EFFECT: enhanced effectiveness of washing and draining purulent lesions; prevented spread.
Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.